PriceTargets.com logo

Vor Biopharma - VOR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.36
  • Forecasted Upside: 797.80%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$1.27 As of 12/30/2024 11:09 AM ET
▼ -0.005 (-0.39%)

This chart shows the closing price for VOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vor Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VOR

Analyst Price Target is $11.36
▲ +797.80% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Vor Biopharma in the last 3 months. The average price target is $11.36, with a high forecast of $17.50 and a low forecast of $3.00. The average price target represents a 797.80% upside from the last price of $1.27.

This chart shows the closing price for VOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Vor Biopharma. This rating has held steady since April 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$12.00 ➝ $12.00
12/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.50 ➝ $17.50
12/9/2024WedbushReiterated RatingOutperform$11.00
11/8/2024WedbushReiterated RatingOutperform$11.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.50 ➝ $17.50
11/8/2024Robert W. BairdLower TargetOutperform ➝ Outperform$22.00 ➝ $14.00
9/6/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$12.00 ➝ $12.00
9/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.50 ➝ $17.50
8/14/2024BarclaysLower TargetOverweight ➝ Overweight$10.00 ➝ $3.00
5/13/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$12.00
5/13/2024OppenheimerReiterated RatingOutperform ➝ Outperform$15.00 ➝ $10.00
5/10/2024WedbushReiterated RatingOutperform ➝ Outperform$11.00
4/23/2024WedbushReiterated RatingOutperform ➝ Outperform$11.00
3/22/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$12.00
3/21/2024Stifel NicolausLower TargetBuy ➝ Buy$15.00 ➝ $12.00
3/21/2024OppenheimerReiterated RatingOutperform ➝ Outperform$17.00 ➝ $15.00
3/21/2024WedbushReiterated RatingOutperform ➝ Outperform$11.00
3/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.50
1/18/2024WedbushReiterated RatingOutperform ➝ Outperform$11.00
11/2/2023WedbushReiterated RatingOutperform$11.00
8/14/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$12.00
8/11/2023Stifel NicolausLower Target$16.00 ➝ $15.00
8/11/2023WedbushLower TargetOutperform ➝ Outperform$18.00 ➝ $11.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$17.50
3/26/2023BarclaysLower Target$15.00 ➝ $10.00
3/24/2023OppenheimerReiterated RatingOutperform$18.00
3/24/2023Truist FinancialLower TargetBuy$17.00 ➝ $16.00
3/24/2023Stifel NicolausLower TargetBuy$17.00 ➝ $16.00
3/24/2023Robert W. BairdLower TargetOutperform$38.00 ➝ $22.00
3/24/2023HC WainwrightLower TargetBuy$20.00 ➝ $17.50
2/13/2023JMP SecuritiesReiterated RatingMarket Outperform$12.00
1/19/2023JMP SecuritiesLower TargetMarket Outperform$15.00 ➝ $12.00
11/14/2022OppenheimerLower TargetOutperform$27.00 ➝ $18.00
11/11/2022BarclaysLower TargetOverweight$26.00 ➝ $15.00
8/15/2022HC WainwrightLower TargetBuy$26.00 ➝ $20.00
7/26/2022WedbushReiterated RatingInitiates
7/25/2022WedbushInitiated CoverageOutperform$18.00
5/16/2022HC WainwrightReiterated RatingBuy$26.00
5/13/2022JMP SecuritiesLower Target$30.00 ➝ $15.00
4/27/2022The Goldman Sachs GroupInitiated CoverageNeutral$6.00
3/21/2022BarclaysLower TargetOverweight$56.00 ➝ $26.00
3/16/2022JMP SecuritiesLower TargetBuy$40.00 ➝ $30.00
3/15/2022HC WainwrightReiterated RatingBuy$26.00
1/24/2022B. RileyLower Target$60.00 ➝ $46.00
12/17/2021HC WainwrightInitiated CoverageBuy$26.00
12/2/2021Robert W. BairdInitiated CoverageOutperform$38.00
12/1/2021OppenheimerInitiated CoverageOutperform$30.00
10/19/2021JMP SecuritiesInitiated CoverageOutperform$40.00
5/7/2021B. RileyReiterated RatingBuy$60.00
3/24/2021B. RileyInitiated CoverageBuy$60.00
3/3/2021BarclaysInitiated CoverageOverweight$56.00
3/2/2021Evercore ISIInitiated CoverageOutperform$48.00
3/2/2021Stifel NicolausInitiated CoverageBuy$58.00
3/2/2021The Goldman Sachs GroupInitiated CoverageSell$19.00
(Data available from 12/30/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Vor Biopharma logo
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.27
Low: $1.22
High: $1.35

50 Day Range

MA: $0.86
Low: $0.68
High: $1.27

52 Week Range

Now: $1.27
Low: $0.63
High: $3.14

Volume

950,869 shs

Average Volume

532,929 shs

Market Capitalization

$86.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vor Biopharma?

The following Wall Street research analysts have issued research reports on Vor Biopharma in the last year: Barclays PLC, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Robert W. Baird, Stifel Nicolaus, and Wedbush.
View the latest analyst ratings for VOR.

What is the current price target for Vor Biopharma?

0 Wall Street analysts have set twelve-month price targets for Vor Biopharma in the last year. Their average twelve-month price target is $11.36, suggesting a possible upside of 794.3%. HC Wainwright has the highest price target set, predicting VOR will reach $17.50 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $3.00 for Vor Biopharma in the next year.
View the latest price targets for VOR.

What is the current consensus analyst rating for Vor Biopharma?

Vor Biopharma currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VOR will outperform the market and that investors should add to their positions of Vor Biopharma.
View the latest ratings for VOR.

What other companies compete with Vor Biopharma?

Other companies that are similar to Vor Biopharma include Aurora Cannabis, Zentalis Pharmaceuticals, DiaMedica Therapeutics, Molecular Partners and ProQR Therapeutics. Learn More about companies similar to Vor Biopharma.

How do I contact Vor Biopharma's investor relations team?

The company's listed phone number is 617-655-6580. The official website for Vor Biopharma is www.vorbiopharma.com. Learn More about contacing Vor Biopharma investor relations.